Overview

• Under the nine-month-old Medizinforschungsgesetz, Eli Lilly finalized an undisclosed net price for its Mounjaro injection with statutory insurers, marking the law’s first application.
• The independent IQWiG assessment found only a minor added benefit in one of eight patient groups and no proven advantage in the rest.
• Doctors and EU reference countries remain unaware of the actual rebate, hindering cost comparisons and prescription decisions.
• The GKV-Spitzenverband warns that hidden rebates inflate costs for insurers without improving care and could saddle contributors with billions in extra expenses.
• Obesity patients continue to pay the full €1,126 list price out of pocket because the Social Code bars statutory coverage for weight-loss medications.